Sodium hydrocarbonate (Solution, Powder) Instructions for Use
ATC Code
B05CB04 (Sodium bicarbonate)
Active Substance
Sodium bicarbonate (BP British Pharmacopoeia)
Clinical-Pharmacological Group
Acidosis correction preparation for parenteral use
Pharmacotherapeutic Group
Blood substitutes and perfusion solutions; solutions for intravenous administration; solutions affecting water-electrolyte balance
Pharmacological Action
Antacid agent, regulates acid-base balance. It has alkaline properties, increases the alkaline reserve of the blood. When taken orally, it quickly neutralizes hydrochloric acid of gastric juice and has a rapid but short-lived antacid effect. It irritates the receptors of the gastric mucosa, increases the release of gastrin with secondary activation of secretion, and may cause discomfort in the stomach (due to its distension) and belching.
It has an expectorant effect by reducing the viscosity of sputum due to a shift in the reaction of bronchial mucus to the alkaline side.
When absorbed, it leads to the development of alkalosis. Urine alkalinization prevents the precipitation of uric acid in the urinary tract.
It alleviates the symptoms of seasickness and airsickness.
Indications
Metabolic acidosis (including in diabetes mellitus, infections, intoxications, kidney diseases, anesthesia, in the postoperative period); as a symptomatic agent for the relief of heartburn, discomfort in the epigastrium associated with increased acidity of gastric juice; symptomatic treatment of cough with viscous and difficult-to-expectorate sputum in various respiratory tract diseases; seasickness and airsickness.
For topical application: inflammatory diseases of the oral cavity, eyes, upper respiratory tract, for softening earwax.
ICD codes
| ICD-10 code | Indication |
| E87.2 | Acidosis |
| H01.0 | Blepharitis |
| H10 | Conjunctivitis |
| H15 | Diseases of sclera |
| H16 | Keratitis |
| H61.2 | Impacted cerumen |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| K04 | Diseases of pulp and periapical tissues (including periodontitis) |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| K29 | Gastritis and duodenitis |
| R05 | Cough |
| R09.3 | Sputum |
| R10.1 | Pain localized to the upper abdomen |
| R12 | Heartburn |
| T75.3 | Motion sickness |
| ICD-11 code | Indication |
| 5C73.Z | Acidosis, unspecified |
| 9A01.3 | Infectious blepharitis |
| 9A02.Z | Inflammatory disorders of eyelid, unspecified |
| 9A60.Z | Conjunctivitis, unspecified |
| 9A71 | Infectious keratitis |
| 9A7Z | Diseases of the cornea, unspecified |
| 9B5Z | Disorders of sclera, unspecified |
| AA42 | Impacted cerumen |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA09.0 | Chronic rhinitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA09.Z | Diseases of pulp and periapical tissues, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| MD10 | Abnormal sputum |
| MD12 | Cough |
| MD81.10 | Pain localized in the upper abdomen |
| MD95 | Heartburn |
| NF08.3 | Motion sickness |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For metabolic acidosis, administer intravenously. The required dose is calculated based on base deficit and body weight. Do not exceed a maximum infusion rate of 50 mL of a 5% solution over 10 minutes. For severe acidosis, administer under strict laboratory control of acid-base balance.
For oral use as an antacid, dissolve 1/2 to 1 teaspoon of powder in 1/2 glass of water. Take symptomatically for heartburn or epigastric pain. Do not use continuously for more than two weeks without medical supervision.
As an expectorant for cough with viscous sputum, use an oral solution. Inhale a 0.5-2% solution via a nebulizer for respiratory tract conditions. Follow specific device instructions for inhalation.
For inflammatory diseases of the oral cavity (gingivitis, stomatitis), use a 1-2% solution for rinsing. Apply 2-3 times daily after meals.
For conjunctivitis and eye diseases, use a 1-2% solution for irrigation. For impacted cerumen, instill a 3-5% warm solution into the external auditory canal.
For motion sickness, take orally as a powder or solution at the first sign of symptoms. Dosage depends on individual tolerance and severity.
Adjust dosage in patients with renal impairment or heart failure due to sodium content. Monitor for signs of hypernatremia or alkalosis, especially with prolonged use.
Adverse Reactions
With prolonged use, the development of alkalosis (sometimes uncompensated) is possible, accompanied by loss of appetite, nausea, vomiting, pain in the epigastric region, anxiety, headaches, and in some severe cases, tetanic convulsions; increased blood pressure, flatulence (when taken orally).
Contraindications
Conditions accompanied by the development of metabolic alkalosis, hypernatremia, hypokalemia.
Use in Pregnancy and Lactation
It should be used with caution during pregnancy and breastfeeding.
Use in Renal Impairment
In patients with concomitant kidney diseases, excessive sodium intake causes edema and heart failure.
Special Precautions
It is not recommended for systematic use because when neutralizing hydrochloric acid of the stomach with sodium bicarbonate, carbon dioxide is released, which has an excitatory effect on the receptors of the gastric mucosa, increases the release of gastrin, and can cause a secondary increase in secretion. Furthermore, with prolonged regular use, urine alkalinization and an increased risk of phosphate stone formation are possible.
Intensive release of CO2 can provoke perforation of the gastrointestinal tract walls.
In patients with concomitant heart or kidney diseases, excessive sodium intake causes edema and heart failure.
Drug Interactions
With simultaneous use, the excretion of amphetamine in the urine decreases due to an increase in urine pH under the influence of sodium bicarbonate.
When sodium bicarbonate is taken orally against the background of the use of lithium carbonate in established maintenance doses, a decrease in the plasma concentration of lithium is possible, which is due to the influence of sodium ions.
With simultaneous use with methotrexate, the excretion of methotrexate in the urine increases and its toxic effect on the kidneys decreases due to an increase in urine pH under the influence of sodium bicarbonate.
With simultaneous oral administration, the absorption of tetracyclines decreases.
Due to an increase in urine pH under the influence of sodium bicarbonate, a delay in the excretion of ephedrine from the body is observed and the risk of side effects (tremor, anxiety, sleep disorders, tachycardia) increases.
With intravenous drip administration of sodium bicarbonate, an enhancement of the antihypertensive effect of reserpine is possible.
Storage Conditions
Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for infusion 5%: 200 ml bottle 1 or 24 pcs., 400 ml bottle 1 or 12 pcs.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
 |
Sodium bicarbonate | Solution for infusion 5%: 200 ml bottle 1 or 24 pcs., 400 ml bottle 1 or 12 pcs. |
Dosage Form, Packaging, and Composition
| Solution for infusion 4% | 100 ml |
| Sodium bicarbonate | 4 g |
Excipients : water for injections up to 100 ml.
100 ml – Glass bottles with a capacity of 100 ml (1) – cardboard packs.
Infusion solution 40 mg/1 ml: bot. 100 ml, 200 ml or 400 ml
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
|
Sodium bicarbonate | Infusion solution 40 mg/1 ml: bot. 100 ml, 200 ml or 400 ml |
Dosage Form, Packaging, and Composition
Solution for infusion transparent, colorless.
| 1 ml | |
| Sodium bicarbonate | 40 mg |
Ionic composition (per 1 liter): sodium ion – 476 mmol, bicarbonate ion – 476 mmol.
Excipients : disodium edetate (disodium salt of ethylenediaminetetraacetic acid) – 0.2 mg, water for injections – up to 1 ml.
Theoretical osmolarity: 952 mOsm/l.
100 ml – bottles (1) – cardboard packs.
200 ml – bottles (1) – cardboard packs.
400 ml – bottles (1) – cardboard packs.
Powder for preparation of oral solution and topical application 10 g: pkg. 10 pcs.
Marketing Authorization Holder
Moscow Pharmaceutical Factory CJS (Russia)
Dosage Form
 |
Sodium bicarbonate | Powder for preparation of oral solution and topical application 10 g: pkg. 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for oral administration and topical application white, crystalline, odorless, salty-alkaline taste; aqueous solutions have an alkaline reaction.
| 1 sachet | |
| Sodium bicarbonate | 10 g |
10 g – sachets (5) – cardboard packs.
10 g – sachets (10) – cardboard packs.
Infusion solution 5%: 100 ml, 200 ml or 400 ml bot.
Marketing Authorization Holder
Mosfarm LLC (Russia)
Dosage Form
|
Sodium bicarbonate | Infusion solution 5%: 100 ml, 200 ml or 400 ml bot. |
Dosage Form, Packaging, and Composition
Solution for infusion transparent, colorless.
| 1 l | |
| Sodium bicarbonate | 50 g |
Excipients : water for injections up to 1 l.
Theoretical osmolarity 1190 mOsm/l.
100 ml – glass bottles (1) – cardboard packs.
200 ml – glass bottles (1) – cardboard packs.
400 ml – glass bottles (1) – cardboard packs.
100 ml – glass bottles (36) – cardboard boxes (for hospitals).
250 ml – glass bottles (15) – cardboard boxes (for hospitals).
250 ml – glass bottles (28) – cardboard boxes (for hospitals).
450 ml – glass bottles (15) – cardboard boxes (for hospitals).
Powder for solution for oral and topical use 25 g: jars
Marketing Authorization Holder
Yaroslavl Pharmaceutical Factory, CJSC (Russia)
Dosage Form
|
Sodium bicarbonate | Powder for solution for oral and topical use 25 g: jars |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for oral administration and topical application | 1 jar |
| Sodium bicarbonate | 25 g |
25 g – dark glass jars.
Powder for preparation of solution for oral and topical administration 10 g: sachets 5 pcs.
Marketing Authorization Holder
Yaroslavl Pharmaceutical Factory, CJSC (Russia)
Dosage Form
|
Sodium bicarbonate | Powder for preparation of solution for oral and topical administration 10 g: sachets 5 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for oral administration and topical application | 1 sachet |
| Sodium bicarbonate | 10 g |
10 g – sachets made of combined heat-sealable material (5) – cardboard packs.
Infusion solution 8.4%: bottle 200 ml 30 pcs.
Marketing Authorization Holder
Liquor, LLC (Armenia)
Dosage Form
|
Sodium bicarbonate | Infusion solution 8.4%: bottle 200 ml 30 pcs. |
Dosage Form, Packaging, and Composition
| Solution for infusion 8.4% | 1 l |
| Sodium bicarbonate | 84 g |
200 ml – bottles (30) – cardboard boxes.
Infusion solution 8.4%: vial 20 ml 30 pcs.
Marketing Authorization Holder
Liquor, LLC (Armenia)
Dosage Form
|
Sodium bicarbonate | Infusion solution 8.4%: vial 20 ml 30 pcs. |
Dosage Form, Packaging, and Composition
| Solution for infusion 8.4% | 1 l |
| Sodium bicarbonate | 84 g |
20 ml – vials (30) – cardboard boxes.
Infusion solution 5%: 100 mL, 200 mL, or 400 mL bottle
Marketing Authorization Holder
Mir Chemical and Pharmaceutical Concern, LLC (Russia)
Dosage Form
|
Sodium bicarbonate-Eskom | Infusion solution 5%: 100 mL, 200 mL, or 400 mL bottle |
Dosage Form, Packaging, and Composition
| Solution for infusion 5% | 1 l |
| Sodium bicarbonate | 50 g |
100 ml – bottles.
200 ml – bottles.
400 ml – bottles.
100 ml – bottles (28) – cardboard boxes.
200 ml – bottles (28) – cardboard boxes.
400 ml – bottles (15) – cardboard boxes.
Infusion solution 42 mg/mL: 100 mL or 200 mL bottle, 1 or 28 pcs., 400 mL bottle, 1 or 15 pcs.
Marketing Authorization Holder
Mir Chemical and Pharmaceutical Concern, LLC (Russia)
Dosage Form
|
Sodium bicarbonate-Eskom | Infusion solution 42 mg/mL: 100 mL or 200 mL bottle, 1 or 28 pcs., 400 mL bottle, 1 or 15 pcs. |
Dosage Form, Packaging, and Composition
| Infusion solution | 1 ml |
| Sodium bicarbonate | 42 mg |
100 ml – bottles.
200 ml – bottles.
400 ml – bottles.
100 ml – bottles (28) – cardboard boxes.
200 ml – bottles (28) – cardboard boxes.
400 ml – bottles (15) – cardboard boxes.
Infusion solution 84 mg/mL: 100 mL or 200 mL bottle, 1 or 28 pcs., 400 mL bottle, 1 or 15 pcs.
Marketing Authorization Holder
Mir Chemical and Pharmaceutical Concern, LLC (Russia)
Dosage Form
|
Sodium bicarbonate-Eskom | Infusion solution 84 mg/mL: 100 mL or 200 mL bottle, 1 or 28 pcs., 400 mL bottle, 1 or 15 pcs. |
Dosage Form, Packaging, and Composition
| Infusion solution | 1 ml |
| Sodium bicarbonate | 84 mg |
100 ml – bottles.
200 ml – bottles.
400 ml – bottles.
100 ml – bottles (28) – cardboard boxes.
200 ml – bottles (28) – cardboard boxes.
400 ml – bottles (15) – cardboard boxes.
![Sodium hydrocarbonate [Solution, Powder] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Sodium hydrocarbonate [Solution, Powder] 2")